Top

Intensive Care Medicine

Published in:

07-06-2022 | COVID-19 | Letter

Increased risk of central line-associated bloodstream infection in COVID-19 patients associated with dexamethasone but not with interleukin antagonists

Authors: Iwan A. Meynaar, Simone van Rijn, Thomas H. Ottens, Nathalie D. van Burgel, Cees van Nieuwkoop

Published in: Intensive Care Medicine | Issue 7/2022

Excerpt

Dear Editor, …

Available only for authorised users

Centers or Disease Control And Prevention. Bloodstream Infection Event (Central Line-Associated Bloodstream Infection and Non-central Line Associated Bloodstream Infection). 2022.

Patel PR, Weiner-Lastinger LM, Dudeck MA, Fike LV, Kuhar DT, Edwards JR et al (2020) Impact of COVID-19 Pandemic on Central Line-Associated Bloodstream Infections during the Early Months of 2020, National Healthcare Safety Network. Infect Control Hosp Epidemiol. https://doi.org/10.1017/ice.2021.108CrossRefPubMedPubMedCentral

Baker MA, Sands KE, Huang SSAIE (2021) The impact of COVID-19 on healthcare-associated infections. Clin Infect Dis. https://doi.org/10.1093/cid/ciab688CrossRefPubMedPubMedCentral

van Paassen J, Vos JS, Hoekstra EM, Neumann KMI, Boot PC, Arbous SM (2020) Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes. Crit Care 24:696. https://doi.org/10.1186/s13054-020-03400-9CrossRefPubMedPubMedCentral

Snow TAC, Saleem N, Ambler G, Nastouli E, Singer M, Arulkumaran N (2021) Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials. Intensive Care Med 47:641–652. https://doi.org/10.1007/s00134-021-06416-zCrossRefPubMedPubMedCentral

Title: Increased risk of central line-associated bloodstream infection in COVID-19 patients associated with dexamethasone but not with interleukin antagonists
Authors: Iwan A. Meynaar
Simone van Rijn
Thomas H. Ottens
Nathalie D. van Burgel
Cees van Nieuwkoop
Publication date: 07-06-2022
Publisher: Springer Berlin Heidelberg
Keywords: COVID-19
Sarilumab
COVID-19
Dexamethasone
Published in: Intensive Care Medicine / Issue 7/2022
Print ISSN: 0342-4642
Electronic ISSN: 1432-1238
DOI: https://doi.org/10.1007/s00134-022-06750-w

At a glance: The STEP trials

Springer Medicine

Increased risk of central line-associated bloodstream infection in COVID-19 patients associated with dexamethasone but not with interleukin antagonists

Excerpt

At a glance: The STEP trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 7/2022

(1 → 3)-β-d-Glucan-guided antifungal therapy in adults with sepsis: the CandiSep randomized clinical trial

Partition of respiratory mechanics in patients with acute respiratory distress syndrome and association with outcome: a multicentre clinical study

Shorter might not always be better: the case for longer antibiotic therapy for Pseudomonas aeruginosa pneumonia. Reply of the Editor in Chief

Nicotine patches in patients on mechanical ventilation for severe COVID-19: a randomized, double-blind, placebo-controlled, multicentre trial

How doctors manage conflicts with families of critically ill patients during conversations about end-of-life decisions in neonatal, pediatric, and adult intensive care

Basic ultrasound skill for intensivists: future scope for expansion of the recommendations of the European Society of Intensive Care Medicine. Author's reply